Default header image

Cytokine Analysis in Dogs with Multicentric Lymphoma treated with Madison-Wisconsin protocol

** Please note this study is closed/completed and no longer recruiting patients ** 

Calvalido J, Wood GA, Mutsaers AJ, Wood D, Sears W, Woods JP. Comparison of serum cytokine levels between dogs with multicentric lymphoma and healthy dogs. Vet Immunol Immunopathol. 2016;182:106-114. doi:10.1016/j.vetimm.2016.10.009


To measure levels of different cytokines in dogs with multicentric lymphoma, before and during treatment with Madison-Wisconsin (CHOP) protocol, to identify new biomarkers as predictors of response to therapy and prognosis.


Lymphoma is one of the most common cancers in dogs and cats.  It comprises 7 to 24% of all canine cancers, with an increasing incidence rate. A similar trend is present in humans, for whom non-Hodgkin’s lymphoma represents 5% of all new cancer cases, the fifth leading cause of cancer deaths, and the second fastest growing cancer in terms of mortality.

Standard treatment of lymphoma in dogs and humans integrates a multi-agent chemotherapy protocol called CHOP. However, response to therapy can vary widely between patients.  A recent interest in identifying biomarkers to better predict a patients’ response to therapy and prognosis has led researchers to investigate the usefulness of cytokines. Cytokines are small proteins released by cells that effect the interaction, communication and behaviour of cells.  This study aims to identify new biomarkers from circulating cytokines in the serum of lymphoma patients.   


  • Study will cover the cost of flow cytometry

Samples required:

  • ≥ 1 ml of extra blood (serum) will be collected from patients from visits/weeks 1-11

Inclusion Criteria:

  • Diagnosis of multicentric lymphoma (cytology or histopathology)
  • Treatment with Madison-Wisconsin (CHOP) protocol at OVC

Exclusion Criteria:

  • Previous chemotherapy treatment or L-asparaginase
  • Treatment with prednisone or any NSAID 2 weeks prior to initiation of treatment
  • Vaccination within the last 4 weeks


  • Dr. Paul Woods (PI)
  • Dr. Jerome Calvalido


Vicky Sabine (PhD), Clinical Research Coordinator, OVC
Email:; Work Cell #: 226-218-0338

Funded by OVC Pet Trust.

<Back to Closed & Completed Trials